Monograph Details
|
|
Infections & Infestations
> Viral infections
|
|
TAMIFLU |
| Manufacturer |
|
Roche Laboratories |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Neuraminidase inhibitor. |
| Generic Name |
|
Oseltamivir (as phosphate) 30mg, 45mg, 75mg; caps. |
| Also |
|
• TAMIFLU ORAL SUSPENSION
|
| Indications |
|
Treatment of uncomplicated acute illness due to influenza infection in patients ≥1year of age who have been symptomatic for ≤2days. Prophylaxis of influenza in patients ≥1year of age. |
| Children |
|
<1yr: not recommended. 1–12yrs: Start within 2 days of symptom onset. Treatment: Treat for 5 days. ≤15kg: 30mg twice daily; 16–23kg: 45mg twice daily; 24–40kg: 60mg twice daily; >40kg: 75mg twice daily. Prophylaxis: Treat for 10 days. ≤15kg: 30mg once daily; 16–23kg: 45mg once daily; 24–40kg: 60mg once daily; >40kg: 75mg once daily. |
| Adults |
|
Start within 2 days of symptom onset or exposure. ≥13yrs: Treatment: 75mg twice daily for 5 days; CrCl 10–30mL/min: 75mg once daily for 5 days. Prophylaxis: after close contact with infected individual: 75mg once daily for at least 10 days; during community outbreak: 75mg once daily for up to 6 weeks; CrCl 10–30mL/min: 75mg every other day or 30mg once daily. |
| Precautions |
|
Not a substitute for influenza vaccination. Hepatic impairment. Chronic cardiac or respiratory disease. Immunocompromised. Monitor for signs of abnormal behavior (esp. in children). Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
Do not administer live attenuated influenza vaccine within 2 weeks prior or 48 hrs after treatment. |
| Adverse Reactions |
|
GI upset, bronchitis, headache, insomnia, vertigo, fatigue; possible neuropsychiatric events (eg, hallucinations, delirium, abnormal behavior). |
| How Supplied |
Caps—10
Susp—25mL (w. oral dispenser) |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
